Navigation Links
InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada

PISCATAWAY, N.J., July 30, 2014 /PRNewswire/ -- InnoPharma, Inc. today announced the first generic launch of Olanzapine for Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is indicated for the rapid control of agitation and disturbed behaviors in patients with schizophrenia or bipolar I mania.

As the developer of this generic injectable drug, InnoPharma has entered into an agreement with Sandoz Canada Inc., pursuant to which Sandoz Canada will make, use, sell, market and distribute Olanzapine Injection in Canada.  

Commenting on today's news, Navneet Puri, Ph.D., President and Chief Executive Officer of InnoPharma, stated, "Today's announcement is a key milestone for InnoPharma, as it represents the first international launch of one of our products.  As such, it demonstrates our ability to work successfully with regulatory agencies outside the United States, thereby extending our footprint and opening up additional revenue opportunities. We are pleased to work with our collaborator, Sandoz Canada, on the launch of this important generic drug."

On July 16, 2014, Pfizer Inc. (NYSE: PFE) and InnoPharma announced that they have entered into an agreement under which Pfizer will acquire InnoPharma. The closing of the transaction is subject to U.S. regulatory approval and is expected to occur during the third quarter.

About InnoPharma, Inc.

InnoPharma is a sterile product development company, focused on developing complex generic and innovative products in injectable and ophthalmic dosage forms. The Company has a broad portfolio of products under development, with formulations including solutions, lyophilized, suspensions, emulsions, liposomes, micelles and lipid complexes. InnoPharma's pipeline includes small molecules with solubility and stability challenges, as well as difficult to produce and characterize polypeptides and carbohydrates. The Company has a comprehensive infrastructure for the development of its products in its state of the art R&D facilities in New Jersey, with the capability to handle potent and cytotoxic molecules. More information can be found at

Zyprexa® is a registered trademark of Eli Lilly and Company

For Further Information Contact:
John C. Deighan
Chief Financial Officer
InnoPharma, Inc.
(732) 885-2939

SOURCE InnoPharma, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
2. InnoPharma Inc. Raises $8 Million in Venture Debt
3. Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation
4. PCI Announces Definitive Agreement to Acquire Penn Pharma
5. Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine
6. Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point
7. Pfenex Announces Closing of Initial Public Offering
8. Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences
9. Drew Crawford Announces Launch of PBM365 Media
10. Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
11. EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology
Post Your Comments:
(Date:12/1/2015)... VERONA, Virginia , 1 de diciembre ... líder en tecnología para cuchillas de precisión, ... un programa de identidad de marca. El ... en el diseño y la ingeniería de ... toda la diferencia". ...
(Date:12/1/2015)... 2015 During the recent 2015 Transcatheter ... Francisco, CA , Medinol Ltd. continued to ... During a satellite symposium, "The BioNIR eDES: The ... Restenosis", a renowned physician panel discussed the key ... Coronary Stent System and the Medinol eDES Coronary ...
(Date:12/1/2015)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... that the company will present at the LD Micro Main ... Luxe Sunset Boulevard Hotel in Los Angeles, CA. ... will present on Thursday, December 3, at 9:00 am Pacific ... register at least 10 minutes prior to the start of ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... Florida Hospital Tampa is the first health care provider in ... of Florida. , vBloc® Therapy is a vagal blocking therapy, delivered via the Maestro® System, ... mass index (BMI) of at least 40 to 45 kg, or a BMI of at ...
(Date:12/1/2015)... ... ... Dr. Paul Vitenas, one of the top cosmetic surgeons in Texas ... the Best Single Physician Practice in the nation. Dr. Vitenas and his practice were ... the industry publication. , Dr. Vitenas said he was very honored to receive ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... the 7th Annual 2015 Golden Bridge Business Awards under the New Products and ... zero capex web based sample management software that helps labs organize ...
(Date:12/1/2015)... ... December 01, 2015 , ... For ... mark the film for accurate interpretation by the radiologist. The marking utensils are ... from Sacramento, Calif., has found a way to alleviate this problem. , He ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December ... a fixed price per sprint agile development contract to support the National Geospatial-Intelligence ... five years, provides software engineering, infrastructure, as well as operations and sustainment support ...
Breaking Medicine News(10 mins):